13-May-2024
No headlines found.
Globe Newswire (Tue, 7-May 8:01 AM ET)
Ardelyx Reports First Quarter 2024 Financial Results and Provides Business Update
Globe Newswire (Thu, 2-May 4:02 PM ET)
Globe Newswire (Wed, 1-May 8:00 AM ET)
Ardelyx to Report First Quarter 2024 Financial Results on May 2, 2024
Globe Newswire (Thu, 18-Apr 8:00 AM ET)
Ardelyx, Inc. Reports Employment Inducement Grants
Globe Newswire (Thu, 28-Mar 4:05 PM ET)
Globe Newswire (Mon, 25-Mar 8:00 AM ET)
Ardelyx to Participate at the Cowen 44th Annual Health Care Conference
Globe Newswire (Tue, 27-Feb 8:00 AM ET)
Ardelyx Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
Globe Newswire (Thu, 22-Feb 4:01 PM ET)
Ardelyx Inc is a biotechnology company focused on the discovery, development, and commercialization of innovative, first-in-class medicines that meet significant unmet medical needs. The company has a proprietary drug discovery and design platform. Its lead product candidate is tenapanor, which aims to reduce the absorption of dietary sodium and phosphorus for the treatment of kidney disease, irritable bowel syndrome with constipation, and hyperphosphatemia in patients with dialysis.
Ardelyx trades on the NASDAQ stock market under the symbol ARDX.
As of May 13, 2024, ARDX stock price climbed to $8.02 with 3,415,996 million shares trading.
ARDX has a beta of 2.02, meaning it tends to be more sensitive to market movements. ARDX has a correlation of 0.10 to the broad based SPY ETF.
ARDX has a market cap of $1.88 billion. This is considered a Small Cap stock.
Last quarter Ardelyx reported $46 million in Revenue and -$.11 earnings per share. This beat revenue expectation by $10 million and exceeded earnings estimates by $.04.
In the last 3 years, ARDX stock traded as high as $10.13 and as low as $.49.
The top ETF exchange traded funds that ARDX belongs to (by Net Assets): XBI, VTI, IWM, VXF, IWO.
ARDX has outperformed the market in the last year with a price return of +86.9% while the SPY ETF gained +28.2%. However, in the short term, ARDX had mixed performance relative to the market. It has underperformed in the last 3 months, returning -9.5% vs +5.8% return in SPY. But in the last 2 weeks, ARDX shares have fared better than the market returning +24.1% compared to SPY +2.1%.
ARDX support price is $7.50 and resistance is $8.04 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ARDX stock will trade within this expected range on the day.